Dresden-based anvajo, a technology company that develops, manufactures and sells innovative solutions for analysing liquids, announced that it has raised €17.7M in a Series A round of funding to support “the launch into the human medicine markets.”
The investment came from pharmaceutical company MEDICE Arzneimittel Pütter GmbH & Co. KG, the Johnsonville Holdings, Inc. fund, and German diagnostics specialists Elber Beteiligungen and Think.Health. Besides, Die BrückenköpfeX also participated in the round.
Decoding fluids at the point of need
Stefan Fraedrich founded anvajo and is currently led by CEO Felix Lambrecht. It is a spin-off diagnostic company from Dresden University of Technology and is a developer and manufacturer of point-of-care solutions for the diagnostic testing of liquids.
The anvajo team has created a portable tool for point-of-care fluid analysis that has the potential to be employed in a range of sectors. The company says, “Our team is working on the world’s most compact universal platform for fluid analysis, the “fluidlab.” It combines the instrument itself, a software suite and multifunctional sample carriers.”
The “fluidlab” combines two central laboratory technologies, Spectroscopy and Microscopy, in one portable diagnostic device. The performance of each test is supported by a custom-designed sample carrier system that functions in processing and delivering the fluid to the analyser.
The system of the “fluidlab” is based on technologies such as holographic microscopy, machine-learning-supported image analysis, mobile embedded hardware, function-integrated optics, and meso- and micro-fluidic sample carriers.
The fluidlab system has several applications in environmental and water analysis, food and feed analysis, human and veterinary medicine, and other scientific disciplines. The device can be used, for instance, in veterinary and human medicine to do fast diagnostic testing of blood, urine, and/or sperm immediately at the point-of-need.
